Biosimilar benefits: cost saving in the NHS
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM
Why are new molecules typically combined with standard chemotherapy?
Using reverse engineering to create biosimilars
Biosimilars in oncology: EHA 2017 session on rituximab